Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Non-GAAP Research and Development (R&D) Expense by Year
Non-GAAP Research and Development (R&D) Expense ($M) ($M)
Merck Non-GAAP Research and Development (R&D) Expense: $15,595M in FY2025, down 12.7% from a year earlier.
Latest, FY2025
15,595
Period ended Dec 31, 2025
Change on a year earlier
-12.7%
17,865 in FY2024
History
5 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Research and development | 15,789 | 19 | 175 | 194 | 15,595”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 2a.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP Research and Development (R&D) Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15,595 | -12.7% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 17,865 | -39.9% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 29,711 | +150.9% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 11,842 | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2020 | Dec 31, 2020 | 9,059 | – | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
Cite this data
StockData. (2026). Merck Non-GAAP Research and Development (R&D) Expense ($M), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/nongaap-rd
See every metric in the Merck KPI table. Data updated Oct 26, 2026.